Hologic Inc
NASDAQ:HOLX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
52.73
75.19
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
HOLX
stock under the Base Case scenario is
81.05
USD.
Compared to the current market price of 74.94 USD,
Hologic Inc
is
Undervalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Hologic Inc.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Hologic’s heavy reliance on its top-tier diagnostic tests and imaging systems leaves it exposed to reimbursement rate fluctuations. If governmental or private payers reduce reimbursements for breast health procedures or molecular tests, the company’s revenue and margins could face significant pressure.
Competitors with newer and more advanced structural or molecular imaging technologies could encroach on Hologic’s market share in key areas like mammography. This threat is intensified by new entrants offering bundled solutions that undercut Hologic’s pricing, reducing its ability to capture upgrades and replacements in hospital systems.
The company’s ongoing acquisitions strategy, particularly in the surgical and aesthetics segments, may undermine its operational efficiency if integration challenges arise. Delays or cost overruns related to folding new businesses into its portfolio would erode the benefits of diversification and put profitability at risk.
Hologic’s leading position in breast health and molecular diagnostics provides a strong competitive moat, especially as demand for precise cancer screenings grows globally. Its well-established distribution networks and reputable brand name help the firm maintain pricing power and customer loyalty.
The company’s focus on consumable tests and service contracts creates a resilient recurring revenue stream. As molecular assays and diagnostic reagents become increasingly critical to healthcare, Hologic stands to benefit from consistent demand regardless of economic cycles.
Hologic’s proven track record of strategic acquisitions, such as in the surgical and aesthetics segments, allows it to expand market reach beyond core women’s health products. These acquisitions bolster its pipeline and help the firm access new revenue streams, reinforcing long-term growth prospects.
Revenue & Expenses Breakdown
Hologic Inc
Balance Sheet Decomposition
Hologic Inc
| Current Assets | 3.7B |
| Cash & Short-Term Investments | 2.2B |
| Receivables | 600.8m |
| Other Current Assets | 864.6m |
| Non-Current Assets | 5.3B |
| PP&E | 559.6m |
| Intangibles | 4.2B |
| Other Non-Current Assets | 557.5m |
| Current Liabilities | 977.2m |
| Accounts Payable | 968m |
| Accrued Liabilities | 577.7m |
| Other Current Liabilities | -568.5m |
| Non-Current Liabilities | 3B |
| Long-Term Debt | 2.5B |
| Other Non-Current Liabilities | 475.8m |
Free Cash Flow Analysis
Hologic Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Hologic Inc
|
Revenue
|
4.1B
USD
|
|
Cost of Revenue
|
-1.8B
USD
|
|
Gross Profit
|
2.3B
USD
|
|
Operating Expenses
|
-1.2B
USD
|
|
Operating Income
|
1.1B
USD
|
|
Other Expenses
|
-502.9m
USD
|
|
Net Income
|
565.7m
USD
|
HOLX Profitability Score
Profitability Due Diligence
Hologic Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Hologic Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
HOLX Solvency Score
Solvency Due Diligence
Hologic Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Hologic Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HOLX Price Targets Summary
Hologic Inc
According to Wall Street analysts, the average 1-year price target for
HOLX
is 76.86 USD
with a low forecast of 70.7 USD and a high forecast of 82.95 USD.
Dividends
Current shareholder yield for
HOLX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
HOLX
stock under the Base Case scenario is
81.05
USD.
Compared to the current market price of 74.94 USD,
Hologic Inc
is
Undervalued by 8%.